Articles published during the last five years in national/ international peer-reviewed journals

2023

• Antagonistic roles of canonical and Alternative-RPA in disease-associated tandem CAG repeat instability. Gall-Duncan T, Luo J, Jurkovic CM, Fischer LA, Fujita K, Deshmukh AL, Harding RJ, Tran S, Mehkary M, Li V, Leib DE, Chen R, Tanaka H, Mason AG, Lévesque D, Khan M, Razzaghi M, Prasolava T, Lanni S, Sato N, Caron MC, Panigrahi GB, Wang P, Lau R, Castel AL, Masson JY, Tippett L, Turner C, Spies M, La Spada AR, Campos EI, Curtis MA, Boisvert FM, Faull RLM, Davidson BL, Nakamori M, Okazawa H, Wold MS, Pearson CE. Cell. 2023 Oct 26;186(22):4898-4919.e25. doi: 10.1016/j.cell.2023.09.008. PMID: 37827155
  
• Msi2 enhances muscle dysfunction in a myotonic dystrophy type 1 mouse model. Sabater-Arcis M, Moreno N, Sevilla T, Perez Alonso M, Bargiela A, Artero R. Biomed J. 2023 Oct 3:100667. doi: 10.1016/j.bj.2023.100667. PMID: 37797921
• Peptide-conjugated antimiRs improve myotonic dystrophy type 1 phenotypes by promoting endogenous MBNL1 expression. González-Martínez I, Cerro-Herreros E, Moreno N, García-Rey A, Espinosa-Espinosa J, Carrascosa-Sàez M, Piqueras-Losilla D, Arzumanov A, Seoane-Miraz D, Jad Y, Raz R, Wood MJ, Varela MA, Llamusí B, Artero R. Mol Ther Nucleic Acids. 2023 Sep 5;34:102024. doi: 10.1016/j.omtn.2023.09.001.  PMID: 37744174
• Natural Compound Boldine Lessens Myotonic Dystrophy Type 1 Phenotypes in DM1 Drosophila Models, Patient-Derived Cell Lines, and HSALR Mice. Álvarez-Abril MC, García-Alcover I, Colonques-Bellmunt J, Garijo R, Pérez-Alonso M, Artero R, López-Castel A. Int J Mol Sci. 2023 Jun 6;24(12):9820.
• BlockmiR AONs as Site-Specific Therapeutic MBNL Modulation in Myotonic Dystrophy 2D and 3D Muscle Cells and HSALR Mice. Overby SJ, Cerro-Herreros E, Espinosa-Espinosa J,  González-Martínez I, Moreno N, Fernández-Costa JM, Balaguer-Trias J, Ramón-Azcón J, Pérez-Alonso M, Møller T, Llamusí B and Artero R. Pharmaceutics 2023, 15(4), 1118. https://doi.org/10.3390/pharmaceutics15041118
• The myotonic dystrophy type 1 drug development pipeline: 2022 edition. Pascual-Gilabert M, Artero R, López-Castel A. Drug Discov Today. 2023 Mar;28(3):103489. doi: 10.1016/j.drudis.2023.103489. PMID: 36634841
• Quantitative magnetic resonance imaging assessment of muscle composition in myotonic dystrophy mice. Bargiela A, Ten-Esteve A, Martí-Bonmatí L, Sevilla T, Perez Alonso M, Artero R. Sci Rep. 2023 Jan 10;13(1):503. doi: 10.1038/s41598-023-27661-w.
• CRISPR-Cas9 editing of a TNPO3 mutation in a muscle cell model of limb-girdle muscular dystrophy type D2. Poyatos-García J, Blázquez-Bernal Á, Selva-Giménez M, Bargiela A, Espinosa-Espinosa J, Vázquez-Manrique RP, Bigot A, Artero R, Vilchez JJ. Mol Ther Nucleic Acids. 2023 Jan 11;31:324-338. doi: 10.1016/j.omtn.2023.01.004.

---

2022

• Role of miRNAs in muscle atrophy: the myotonic dystrophy paradigm. González-Barriga A, Artero R, and López-Castel A . MicroRNA. Academic Press, 2022. 331-362.
• Editorial: Muscular dystrophies: Current therapeutic advances to improve and restore muscle homeostasis. Bargiela A, Hernández-Torres F. Front Cell Dev Biol. 2022 Aug 31;10:1009439. doi: 10.3389/fcell.2022.1009439.
  
• Moxifloxacin rescues SMA phenotypes in patient-derived cells and animal model. Januel C, Menduti G, Mamchaoui K, Martinat C, Artero R, Konieczny P, Boido M. Cell Mol Life Sci. 2022 Jul 22;79(8):441. doi: 10.1007/s00018-022-04450-8. PMID: 35864358
• Proof of concept of peptide-linked blockmiR-induced MBNL functional rescue in myotonic dystrophy type 1 mouse model. Overby SJ, Cerro-Herreros E, Gonzalez-Martinez I, Varela MA, Seoane-Miraz D, Jad Y, Raz R, Møller T, Pérez-Alonso M, Wood MJ, Llamusí B, Artero R. Mol Ther Nucleic Acids. 2022 Mar 8; 27:1146-1155.
• Deciphering the Complex Molecular Pathogenesis of Myotonic Dystrophy Type 1 through Omics Studies. Espinosa-Espinosa J, González-Barriga A, López-Castel A, Artero R. Int J Mol Sci. 2022 Jan 27;23(3):1441. doi: 10.3390/ijms23031441. PMID: 35163365
• Rapid Determination of MBNL1 Protein Levels by Quantitative Dot Blot for the Evaluation of Antisense Oligonucleotides in Myotonic Dystrophy Myoblasts. Moreno N, González-Martínez I, Artero R, Cerro-Herreros E. Methods in Molecular Biology book series (MIMB, volume 2434). 22 Jan 1.

---

2021

• The Development of SARS-CoV-2 Variants: The Gene Makes the Disease. R Perez-Gomez. J Dev Biol. 2021 Dec 15;9(4):58. doi: 10.3390/jdb9040058. PMID: 34940505
• Musashi-2 contributes to myotonic dystrophy muscle dysfunction by promoting excessive autophagy through miR-7 biogenesis repression. Sabater-Arcis M, Bargiela A, Moreno N, Poyatos-Garcia J, Vilchez JJ, Artero R.  Mol Ther Nucleic Acids. 2021 Aug 19;25:652-667. doi: 10.1016/j.omtn.2021.08.010. PMID: 34589284; PMCID: PMC8463325.
• Inhibition of autophagy rescues muscle atrophy in a LGMDD2 Drosophila model. Blázquez-Bernal Á, Fernandez-Costa JM, Bargiela A, Artero R. . FASEB J. 2021 Oct;35(10):e21914. doi: 10.1096/fj.202100539RR. PMID: 34547132.
• Defined D-hexapeptides bind CUG repeats and rescue phenotypes of myotonic dystrophy myotubes in a Drosophila model of the disease. Rapisarda A, Bargiela A, Llamusi B, Pont I, Estrada-Tejedor R, Garcia-España E, Artero R, Perez-Alonso M. Sci Rep. 2021 Sep 30;11(1):19417. doi: 10.1038/s41598-021-98866-0. PMID: 34593893
  
• Practicing logical reasoning through Drosophila segmentation gene mutants. Bargiela A, Artero R. Biochem Mol Biol Educ. 2021 Sep;49(5):729-736. doi: 10.1002/bmb.21554. Epub 2021 Jun 23. PMID: 34160891.
• Neuroprotective properties of queen bee acid by autophagy induction. Martínez-Chacón G, Paredes-Barquero M, Yakhine-Diop SMS, Uribe-Carretero E, Bargiela A, Sabater-Arcis M, Morales-García J, Alarcón-Gil J, Alegre-Cortés E, Canales-Cortés S, Rodríguez-Arribas M, Camello PJ, Pedro JMB, Perez-Castillo A, Artero R, Gonzalez-Polo RA, Fuentes JM, Niso-Santano M. Cell Biol Toxicol. 2021 Aug 27. doi: 10.1007/s10565-021-09625-w. Epub ahead of print. PMID: 34448959.
• Preclinical characterization of antagomiR-218 as a potential treatment for Myotonic Dystrophy. Cerro-Herreros E, González-Martínez I, Moreno N, Espinosa-Espinosa J, Fernández-Costa JM, Colom-Rodrigo A, Overby SJ, Seoane-Miraz D, Poyatos-García J, Vilchez JJ, López de Munain A, Varela MA, Wood MJ, Pérez-Alonso M, Llamusí B, Artero R. Mol Ther Nucleic Acids. 2021 Jul 29;26:174-191. doi: 10.1016/j.omtn.2021.07.017. PMID: 34513303; PMCID: PMC8413838.
• Rabphilin silencing causes dilated cardiomyopathy in a Drosophila model of nephrocyte damage. Selma-Soriano E, Casillas-Serra C, Artero R, Llamusi B, Navarro JA, Redón J.  Sci Rep. 2021 Jul 27;11(1):15287. doi: 10.1038/s41598-021-94710-7. PMID: 34315987.
• Bioengineered in vitro 3D model of myotonic dystrophy type 1 human skeletal muscle.  Fernández-Garibay X, Ortega MA, Cerro-Herreros E, Comelles J, Martínez E, Artero R, Fernandez-Costa JM, Ramon J.  Biofabrication. 2021 Apr 9. doi: 10.1088/1758-5090/abf6ae. PMID: 33836519.
• Myotonic dystrophy type 1 drug development: A pipeline toward the market. Pascual-Gilabert M, López-Castel A, Artero R.  Drug Discov Today. 2021 Mar 31:S1359-6446(21)00160-4. doi: 10.1016/j.drudis.2021.03.024. PMID: 33798646.
• Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). Klionsky DJ, et al.  Autophagy. 2021 Feb 8:1-382. doi: 10.1080/15548627.2020.1797280. PMID: 33634751.
• The hallmarks of myotonic dystrophy type 1 muscle dysfunction. Ozimski LL, Sabater-Arcis M, Bargiela A, Artero R. Biol Rev Camb Philos Soc. 2021 Apr;96(2):716-730. doi: 10.1111/brv.12674. Epub 2020 Dec 2. 2020 Dec 2. doi: 10.1111/brv.12674. PMID: 33269537.

---

2020

• Design of novel small molecule base-pair recognizers of toxic CUG RNA transcripts characteristics of DM1. Ondono R, Lirio Á, Elvira C, Álvarez-Marimon E, Provenzano C, Cardinali B, Pérez-Alonso M, Perálvarez-Marín A, Borrell JI, Falcone G, Estrada-Tejedor R.Comput Struct Biotechnol J. 2020 Dec 6;19:51-61. doi: 10.1016/j.csbj.2020.11.053. PMID: 33363709; PMCID: PMC7753043.
• Therapeutic potential of antagomiR-23b for treating Myotonic Dystrophy. Cerro-Herreros E, González-Martínez I, Moreno-Cervera N, Pérez-Alonso M, Llamusí B, Artero R. Mol Ther Nucl Acids. 2020
• Rabphilin involvement in filtration and molecular uptake in Drosophila nephrocytes suggests a similar role in human podocytes. Selma-Soriano E, Llamusi B, Fernández-Costa JM, Ozimski LL, Artero R, Redón J. Dis Model Mech. 2020
• Protective effects of mirtazapine in mice lacking the Mbnl2 gene in forebrain glutamatergic neurons: Relevance for myotonic dystrophy 1. Ramon-Duaso C, Rodríguez-Morató J, Selma-Soriano E, Fernández-Avilés C, Artero R, de la Torre R, Pozo ÓJ, Robledo P. Neuropharmacology 2020 
• miR-7 Restores Phenotypes in Myotonic Dystrophy Muscle Cells by Repressing Hyperactivated Autophagy. Sabater-Arcis M, Bargiela A, Furling D, Artero R. Mol Ther Nucleic Acids 2020 
• Drosophila SMN2 minigene reporter model identifies moxifloxacin as a candidate therapy for SMA. Konieczny P, Artero R. FASEB J 2020

---

2019

• MicroRNA-Based Therapeutic Perspectives in Myotonic Dystrophy. López Castel A, Overby SJ, Artero R. Int J Mol Sci 2019 ​
• Increased Muscleblind levels by chloroquine treatment improve myotonic dystrophy type 1 phenotypes in in vitro and in vivo models. Bargiela, Sabater-Arcis, Espinosa-Espinosa J, Zulaica M, Lopez de Munain A, Artero R. Proc Natl Acad Sci U S A 2019

---

2018

• miR-23b and miR-218 silencing increase Muscleblind-like expression and alleviate myotonic dystrophy phenotypes in mammalian models.  Cerro-Herreros E, Sabater-Arcis M, Fernandez-Costa JM, Moreno N, Perez-Alonso M, Llamusi B, Artero R. Nat Commun. 2018.
• Muscleblind-like 1 regulates epithelial to mesenchymal transition markers in triple-negative breast cancer. Adam Artigues A, Tormo E, Cerro-Herreros E, Sabater M, Garrido-Cano I, Pineda Merlo B, Pattanayak B, Cabello P, Artero R, Eroles P. Ann Oncol  2018
• Targeting RNA structure in SMN2 reverses spinal muscular atrophy molecular phenotypes. Garcia-Lopez A, Tessaro F, Jonker HRA, Wacker A, Richter C, Comte A, Berntenis N, Schmucki R, Hatje K, Petermann O, Chiriano G, Perozzo R, Sciarra D, Konieczny P, Faustino I, Fournet G, Orozco M, Artero R, Metzger F, Ebeling M, Goekjian P, Joseph B, Schwalbe H, Scapozza L. Nat Commun. 2018 
• rbFOX1/MBNL1 competition for CCUG RNA repeats binding contributes to myotonic dystrophy type 1/type 2 differences.  Sellier C, Cerro-Herreros E, Blatter M, Freyermuth F, Gaucherot A, Ruffenach F, Sarkar P, Puymirat J, Udd B, Day JW, Meola G, Bassez G, Fujimura H, Takahashi MP, Schoser B, Furling D, Artero R, Allain FHT, Llamusi B, Charlet-Berguerand N. Nat Commun. 2018 
• Optical Cross-Sectional Muscle Area Determination of Drosophila Melanogaster Adult Indirect Flight Muscles. Selma-Soriano E, Artero R, Llamusi B. J Vis Exp. 2018
• Daunorubicin reduces MBNL1 sequestration caused by CUG-repeat expansion and rescues cardiac dysfunctions in a Drosophila model of myotonic dystrophy. Chakraborty M, Sellier C, Ney M, Pascal V, Charlet-Berguerand N, Artero R, Llamusi B. Dis Model Mech. 2018 
• The Drosophila junctophilin gene is functionally equivalent to its four mammalian counterparts and is a modifier of a Huntingtin poly-Q expansion and the Notch pathway. Calpena E, López Del Amo V, Chakraborty M, Llamusí B, Artero R, Espinós C, Galindo MI. Dis Model Mech. 2018